Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Editas Medicine, Inc. is a biotechnology company focused on developing transformative gene-editing medicines using CRISPR-based technologies. The company operates within the biotechnology and genomic medicine industries, with a primary emphasis on treating serious diseases caused by genetic mutations. Its core value proposition lies in leveraging precise genome-editing tools to enable potentially curative, one-time therapies.
The company’s primary business centers on the discovery, development, and potential commercialization of gene-editing therapies, with a historical focus on ocular, hematologic, and immunologic diseases. Editas Medicine was founded in 2013 by a group of leading scientists in genome editing, including pioneers in CRISPR technology, and became publicly traded in 2016. Over time, the company has refined its strategy, narrowing its pipeline to focus on programs with clearer clinical and regulatory pathways while discontinuing or partnering non-core assets.
Business Operations
Editas Medicine generates value through the research and development of gene-editing therapeutics rather than commercial product sales, as it does not currently have an approved therapy on the market. Its operations are organized around its internal R&D programs and platform development, primarily utilizing CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) gene-editing systems. The company’s lead clinical and preclinical programs target diseases such as sickle cell disease and in vivo ocular indications.
Operations are primarily based in the United States, with laboratory and corporate functions centered in Massachusetts. The company has historically relied on strategic collaborations and licensing arrangements to access intellectual property and, in some cases, to share development costs. Editas Medicine controls key gene-editing patents through licenses and internal development, while also managing a portfolio of discontinued or deprioritized programs as part of capital allocation discipline.
Strategic Position & Investments
Editas Medicine’s strategic direction emphasizes pipeline prioritization, capital efficiency, and advancement of high-impact gene-editing therapies toward clinical proof of concept. Growth initiatives have included focusing resources on lead candidates with strong scientific rationale and clearer regulatory prospects, while reducing spending on early-stage or non-core programs. The company has also pursued selective restructuring initiatives to extend its cash runway and align expenses with near-term milestones.
The company’s notable assets include its wholly owned therapeutic programs and its proprietary gene-editing know-how rather than a broad subsidiary structure. Editas Medicine has engaged in collaborations and licensing agreements with industry and academic partners, though it does not currently operate a diversified portfolio of subsidiaries or majority-owned joint ventures. Its involvement in emerging technologies is concentrated in next-generation CRISPR editing approaches, including improved delivery methods and editing efficiency.
Geographic Footprint
Editas Medicine is headquartered in Cambridge, Massachusetts, within a major global biotechnology hub. Its operational footprint is primarily domestic, with research, development, and administrative activities concentrated in the United States. The company does not maintain large-scale international manufacturing or commercial operations.
Despite its U.S.-centric operations, Editas Medicine maintains a global outlook through participation in international clinical research standards, regulatory engagement, and scientific collaboration. Its intellectual property strategy and potential future commercialization plans are designed to support expansion into North America, Europe, and other major healthcare markets if therapies receive regulatory approval.
Leadership & Governance
Editas Medicine is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development. The leadership’s stated philosophy emphasizes scientific rigor, patient-focused development, and disciplined capital management to navigate the high-risk nature of gene-editing innovation.
Key members of the leadership team include:
- Gilmore O’Neill – President and Chief Executive Officer
- Mark S. Shearman, Ph.D. – Executive Vice President and Chief Scientific Officer
- Linda C. Burkly, Ph.D. – Executive Vice President, Chief Scientific Officer (former role, now advisory capacity; data inconclusive based on available public sources regarding current formal title)
- Michelle L. Robertson – Chief Financial Officer
The company is governed by a board of directors composed of executives, scientific leaders, and industry veterans who provide oversight on strategy, risk management, and corporate governance, consistent with U.S. public company standards.